PMID- 18167242
OWN - NLM
STAT- MEDLINE
DCOM- 20080630
LR  - 20181201
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 87
IP  - 38
DP  - 2007 Oct 16
TI  - [Influence of atorvastatin on the expression of monocyte chemoattractant 
      protein-1 in peritoneal mesothelial cells by high glucose].
PG  - 2677-80
AB  - OBJECTIVE: To investigate the influence of atorvastatin (ATOR) on the expression 
      of monocyte chemoattractant protein-1 (MCP-1) induced by high concentration 
      glucose in peritoneal mesothelial cells (PMCs) and the possible mechanism 
      thereof. METHODS: Rt PMCs were isolated, cultured, passaged, and divided into 3 
      groups: (1) treated with glucose of the concentrations of 0.1, 1.5, 2.5, 4.25% 
      respectively, (2) treated with 1.5% glucose for 0, 0.5, 1, 3, 12, 24, and 48 h 
      respectively, (3) pretreated with ammonium pyrrolidinedithiocarbomate (PDTC) of 
      the concentrations of 5, 10, 25, or 50 micromol/L for 2 h, and then treated with 
      1.5% glucose for 3 h; and (4) pretreated with ATOR of the concentrations of 0.1, 
      1, or 10 mmol/L for 24 h, and then treated with 1.5% glucose for 3 h. Western 
      blotting was used to measure the expression of MCP-1, p65, and inhibitor of 
      nuclear factor-kappaBalpha (IkappaBalpha). RT-PCR was used to measure the 
      expression of MCP-1 mRNA. RESULTS: PMCs expressed MCP-1 in the normal condition. 
      Glucose dose- and time-dependently reduced the protein expression of IkappaBalpha 
      in the PMCs and increased the p65 expression in the nucleus, and accelerated the 
      PMCs to express MCP-1 mRNA and protein (P < 0.05 and P < 0.01). PDTC 
      dose-dependently inhibited the acceleration of expression of MCP-1 mRNA and 
      protein in the PMCs induced by high concentration glucose (P < 0.05 or P < 0.01). 
      ATOR dose-dependently increased the IkappaBalpha expression, decreased the p65 
      expression in nucleus, and decreased the expression of MCP-1 mRNA and protein (P 
      < 0.05 or P < 0.01). CONCLUSION: High concentration glucose induces PMCs to 
      express MCP-1 in a time- and dose-dependent manner. Nuclear factor- kappaB 
      (NF-kappaB) takes part in this regulation. ATOR inhibits PMCs to express MCP-1 
      through inhibiting NF-kappaB pathway.
FAU - Li, Zhi-ming
AU  - Li ZM
AD  - Department of Nephrology, First Affiliated Hospital of China Medical University, 
      Shenyang 110001, China.
FAU - Ma, Jian-fei
AU  - Ma JF
FAU - Wang, Li-ning
AU  - Wang LN
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Chemokine CCL2)
RN  - 0 (Heptanoic Acids)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Nfkbia protein, rat)
RN  - 0 (Pyrroles)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factor RelA)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
RN  - A0JWA85V8F (Atorvastatin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Atorvastatin
MH  - Blotting, Western
MH  - Cells, Cultured
MH  - Chemokine CCL2/*biosynthesis/genetics
MH  - Dose-Response Relationship, Drug
MH  - Epithelial Cells/cytology/*drug effects/metabolism
MH  - Gene Expression/drug effects
MH  - Glucose/*pharmacology
MH  - Heptanoic Acids/*pharmacology
MH  - I-kappa B Proteins/biosynthesis
MH  - Male
MH  - NF-KappaB Inhibitor alpha
MH  - Peritoneum/cytology
MH  - Pyrroles/*pharmacology
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Time Factors
MH  - Transcription Factor RelA/biosynthesis
EDAT- 2008/01/03 09:00
MHDA- 2008/07/01 09:00
CRDT- 2008/01/03 09:00
PHST- 2008/01/03 09:00 [pubmed]
PHST- 2008/07/01 09:00 [medline]
PHST- 2008/01/03 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2007 Oct 16;87(38):2677-80.